Fortrea Holdings Inc.

Healthcare

NASDAQ:FTRE · NASDAQ Global Select

Market Cap $1.45B Beta 2.11 P/E (TTM) -3.1

$15.31 -0.46%

-$0.07 today

52W Low $4.36High $18.67

Vol 2.48M · Avg 1.31M

EPS (TTM) -$4.90Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+200.20%

Period High

$18.40

Period Low

$4.45

Latest

$15.31

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

AnaptysBio, Inc.

NASDAQ:ANAB

$2.39B

Vir Biotechnology, Inc.

NASDAQ:VIR

$1.53B

ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

$1.48B

EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

$1.13B

Xencor, Inc.

NASDAQ:XNCR

$928.99M

Kura Oncology, Inc.

NASDAQ:KURA

$852.68M

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

$850.81M

Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

$736.36M

BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

$610.02M

ProKidney Corp.

NASDAQ:PROK

$262.12M

What is the latest FTRE filing?

The latest filing shown is 4 dated Jun 12, 2026.

How many recent filings does FTRE have?

Intrinsic Alpha currently shows 20 recent filings for FTRE.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.